Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Salt Lake City-based pharmaceutical company Clene Inc. has amended its grant subaward with Columbia University, securing up ...

MAID is currently legal in 10 states and Washington, D.C., but eight other states are considering similar laws this year.

After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...

A New Bedford man was sentenced to prison in federal court on Friday for stealing over $450,000 in disability benefits that ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that it has received approval from USFDA to ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Zydus has announced that the USFDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for ...